Scientists at École Polytechnique Fédérale Lausanne (EPFL), and at UNIL-CHUV, University Hospital Lausanne (CHUV) and University of Lausanne (UNIL) have developed a computational method to create ...

One of the most exciting advances in cancer treatments in the past decade is the development of T cell immunotherapies, in which a patient's own immune system is trained to recognize and attack ...

Cancer immunotherapy, especially using T cells, is showing a lot of promise in treating blood cancers. Bioengineered T cells, especially those equipped with chimeric antigen receptors (CAR-T cells), ...

BRCA1-Associated Protein 1 and Enhancer of Zeste Homolog 2: Pathway Interaction and Therapeutic Intervention in Breast Cancer, Mesothelioma, and Lymphoma The introduction of T-cell–based therapeutics ...

Much of the challenge in developing cancer therapies is determining methods to improve the effectiveness of the immune system’s ability to identify and kill cancer cells. While therapies like CAR T ...

A team of researchers has successfully created more effective immune cells that can fight cancer without damaging healthy tissue. "This story goes back nearly 20 years," says Prof. Paul François. This ...

MONT-SAINT-GUIBERT, Belgium, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of ...

Imviva Biotech, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, today announced that it will present data on CTA313, its investigational ...

Tirabrutinib for the treatment of relapsed or refractory primary central nervous system lymphoma: Efficacy and safety from the phase II PROSPECT study. This is an ASCO Meeting Abstract from the 2025 ...

The gray portion of this schematic represents a nanodisc, where for the first time researchers were able to replicate the native membrane environment (red dots) of a T-cell receptor (cyan). One of the ...